Metagenomi Announces Participation in March Investor Conferences

Metageno­mi, a genet­ic med­i­cines com­pa­ny with a ver­sa­tile port­fo­lio of next-gen­er­a­tion gene edit­ing tools, today announced that it will par­tic­i­pate in two upcom­ing investor conferences.

  • TD Cowen’s 43rd Annu­al Health Care Con­fer­ence
    March 7, 2023
    Par­tic­i­pants: Bri­an C. Thomas, PhD, CEO and Founder, Metageno­mi; Jian Irish, PhD, MBA, Pres­i­dent and COO, Metageno­mi; Simon Harnest, CIO and SVP, Strat­e­gy, Metageno­mi
  • Bar­clays Glob­al Health­care Con­fer­ence
    March 16, 2023
    Par­tic­i­pant: Simon Harnest, CIO and SVP, Strat­e­gy, Metagenomi

About Metageno­mi

Metageno­mi is a gene edit­ing com­pa­ny com­mit­ted to devel­op­ing poten­tial­ly cura­tive ther­a­peu­tics by lever­ag­ing a pro­pri­etary tool­box of next-gen­er­a­tion gene edit­ing sys­tems to accu­rate­ly edit DNA where cur­rent tech­nolo­gies can­not. Our metage­nomics-pow­ered dis­cov­ery plat­form and ana­lyt­i­cal exper­tise reveal nov­el cel­lu­lar machin­ery sourced from oth­er­wise unknown organ­isms. We adapt and forge these nat­u­ral­ly evolved sys­tems into pow­er­ful gene edit­ing sys­tems that are ultra small, extreme­ly effi­cient, high­ly spe­cif­ic and have a decreased risk of immune response. These sys­tems fuel our pipeline of nov­el med­i­cines. Our goal is to rev­o­lu­tion­ize gene edit­ing for the ben­e­fit of patients around the world. For more infor­ma­tion, please vis­it https://​metageno​mi​.co.